Professor Andrew Pettitt

Improving treatment for lymphoma

Improving treatment for lymphoma

Professor Andrew Pettitt is a leading expert on leukaemia and lymphoma at the University of Liverpool. He is working to improve treatment for these diseases and save more lives.

Professor Pettitt is leading several important clinical trials, including a trial called PACIFICO that’s aiming to find the best way to treat older people with follicular lymphoma, the most common type of non-Hodgkin lymphoma.

The other trials he’s leading – CONTINUUM and RIAlto – are testing new combinations of treatments in patients whose leukaemia has come back, or patients that experience severe side effects on standard therapy.

New tests and tailored treatments

To develop new tests for use during cancer treatment, researchers rely on blood and tissue samples from patients who take part in clinical trials. Professor Pettitt has set up a collection of samples from national clinical trials testing treatments for chronic lymphocytic leukaemia (CLL).

He’s using this resource to find new ways of predicting which people with CLL are likely to benefit from specific treatments, and spotting who is more susceptible to certain side effects. This could lead to more personalised approaches to treat leukaemia and lymphoma, which saving more lives and helping to reduce side effects.

Leukaemia
Lymphoma
Biomarker research
Clinical trials

Royal Liverpool University Hospital, Liverpool

arp@liverpool.ac.uk

Website